Affimed N.V.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Price sits at 13% of its 52-week range.
Current Price
$0.18
+0.00%Affimed N.V. (AFMD) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Affimed N.V.'s financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $965180.77. Gross profit (TTM) is $965180.77. EBITDA is $-73.24M. Earnings per share (EPS) is $-7.88. The P/E ratio is -0.03. Market capitalization is $2.78M.
Free cash flow (FCF) is $-126.66M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY17 to FY23. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Affimed N.V.'s financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
